1. Scrip
  2. >>Business

Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition

No Revlimid Sales In Q2

 
• By Vibha Ravi

Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.

M&As As Part Of Growth Strategy
Acquisitions Are Part Of Zydus' Specialty Growth Strategy • Source: Shutterstock

Zydus Lifesciences Limited expects $100m in sales from specialty products like drugs for rare/orphan diseases over three to five years and will continue to pursue organic opportunities as well as acquisitions in pursuit of this goal.

“We are looking to at least add two to three more products - we have at least two under our own development and we continue to look for two or three more assets on the M&A front which are late stage or near to commercial approval,” said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.